scholarly journals Evaluation of Selected Honey and One of Its Phenolic Constituent Eugenol against L1210 Lymphoid Leukemia

2014 ◽  
Vol 2014 ◽  
pp. 1-3 ◽  
Author(s):  
Saravana Kumar Jaganathan ◽  
Dilip Mondhe ◽  
Z. A. Wani ◽  
Eko Supriyanto
Keyword(s):  
Animal Model ◽  
Prime Factor ◽  
Recent Decade ◽  
L1210 Leukemia ◽  
Antileukemic Activity ◽  
Lymphoid Leukemia ◽  
Phenolic Constituents ◽  
Antileukemic Effect ◽  
Deadly Disease ◽  
Phenolic Constituent

People affected with leukemia are on the rise and several strategies were employed to thwart this deadly disease. Recent decade of research focuses on phenolic constituents as a tool for combating various inflammatory, cancer, and cardiac diseases. Our research showed honey and its phenolic constituents as crusaders against cancer. In this work, we explored the antileukemic activity of selected honey and one of its phenolic constituent eugenol against L1210 leukemia animal model. Results of this experiment showed that the selected honey samples as well as eugenol after intraperitoneal injection could not increase the median survival time (MST) of animals. Further, there was only slight marginal increase in the %T/Cvalues of honey and eugenol treated groups. The number of phenolics present in the honey may not be a prime factor to promote antileukemic effect since there was no difference in the MST of two different honeys tested. This study limits the use of selected honey and eugenol against leukemia animal model.

scholarly journals KML001 and doxercalciferol induce synergistic antileukemic effect in acute lymphoid leukemia cells

2017 ◽  
Vol 38 (1) ◽  
pp. 481-487 ◽  
Author(s):  
Yang Liu ◽  
Dong-Yeop Shin ◽  
Somi Oh ◽  
Sujong Kim ◽  
Youngil Koh ◽  
...  
Keyword(s):  
Leukemia Cells ◽  
Lymphoid Leukemia ◽  
Acute Lymphoid Leukemia ◽  
Antileukemic Effect

Effect of 5-Fluorouracil Administered at Low Doses on Cytotoxic Properties of Methotrexate in the in vivo Model of Mice L1210 Leukemia; According to the Schedule of Treatment

Pteridines ◽  
1994 ◽  
Vol 5 (2) ◽  
pp. 55-60
Author(s):  
Julita Graczyk
Keyword(s):  
Survival Time ◽  
Leukemic Cells ◽  
In Vivo Model ◽  
Low Doses ◽  
Simultaneous Administration ◽  
L1210 Leukemia ◽  
Lymphoid Leukemia ◽  
Cytotoxic Effects

Summary The study compared antineoplastic effects of combined methotrexate and 5-fluorouracil therapy on LI210 lymphoid leukemia in mice according to the schedule of treatment. Methotrexate was administered at doses of: LOw.. 0.5 LOw. 5-Fluorouracil was administered at doses of: 0.2 LOIO, 0.1 LOw, 0.02 LOro. The parameters characterizing the efficacy of the therapy were survival time of mice inoculated with LI2l0 leukemic cells .. as well as 1151 excretory capacity of mice inoculated with 1251-iododeoxyuridine-Iabelled leukemic cells. It has been observed that the longest survival time of mice with LI210 leukemia is obtained when methotrexate is administered prior to 5-fluorouracil. Reversing the schedule, or simultaneous administration of the drugs results in shorter survival time. despite the administration of 5-fluorouracil at low doses, ineffective on LI210 leukemia in monotherapy. Cytotoxic effects on LI210 leukemic cells labelled with 1151UDR were present only when methotrexate was administered prior to 5-fluorouracil.

scholarly journals Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome–Positive Lymphoid Leukemia

2015 ◽  
Vol 15 (1) ◽  
pp. 94-105 ◽  
Author(s):  
Atsushi Nemoto ◽  
Satoshi Saida ◽  
Itaru Kato ◽  
Jiro Kikuchi ◽  
Yusuke Furukawa ◽  
...  
Keyword(s):  
Philadelphia Chromosome ◽  
Antileukemic Activity ◽  
Lymphoid Leukemia ◽  
Philadelphia Chromosome Positive

scholarly journals Attenuating homologous recombination stimulates an AID-induced antileukemic effect

2013 ◽  
Vol 210 (5) ◽  
pp. 1021-1033 ◽  
Author(s):  
Kristin R. Lamont ◽  
Muneer G. Hasham ◽  
Nina M. Donghia ◽  
Jane Branca ◽  
Margaret Chavaree ◽  
...  
Keyword(s):  
Homologous Recombination ◽  
Somatic Hypermutation ◽  
Cytidine Deaminase ◽  
Lymphocytic Leukemia ◽  
Disulfonic Acid ◽  
Dna Breaks ◽  
New Paradigm ◽  
Lymphoid Leukemia ◽  
Antileukemic Effect ◽  
B Lymphoid

Activation-induced cytidine deaminase (AID) is critical in normal B cells to initiate somatic hypermutation and immunoglobulin class switch recombination. Accumulating evidence suggests that AID is also prooncogenic, inducing cancer-promoting mutations or chromosome rearrangements. In this context, we find that AID is expressed in >40% of primary human chronic lymphocytic leukemia (CLL) cases, consistent with other reports. Using a combination of human B lymphoid leukemia cells and mouse models, we now show that AID expression can be harnessed for antileukemic effect, after inhibition of the RAD51 homologous recombination (HR) factor with 4,4′-diisothiocyanatostilbene-2-2′-disulfonic acid (DIDS). As a proof of principle, we show that DIDS treatment inhibits repair of AID-initiated DNA breaks, induces apoptosis, and promotes cytotoxicity preferentially in AID-expressing human CLL. This reveals a novel antineoplastic role of AID that can be triggered by inhibition of HR, suggesting a potential new paradigm to treat AID-expressing tumors. Given the growing list of tumor types with aberrant AID expression, this novel therapeutic approach has potential to impact a significant patient population.

scholarly journals PHARMACOLOGICAL EFFECT OF AMINOFERROCENE IN MICE WITH L1210 LEUKEMIA

2015 ◽  
Vol 37 (2) ◽  
pp. 120-125 ◽  
Author(s):  
V F Chekhun ◽  
A Mokhir ◽  
S Daum ◽  
I Todor ◽  
N Yu Lukianova ◽  
...  
Keyword(s):  
Biological Effects ◽  
Leukemia Cell ◽  
Annexin V ◽  
Active Species ◽  
L1210 Leukemia ◽  
Lymphoid Leukemia ◽  
Thiol Compounds ◽  
Free Iron ◽  
Nonprotein Thiol

Aim: To study the cytostatic and some biological effects of aminoferrocene using mice with L1210 lymphoid leukemia. Materials and Methods: Experiments were performed on BDF1 male mice (DBA/2, female × C57Bl/6, male) with transplantable L1210 lymphoid leukemia. Determination of antitumor activity of Benzyl-Fc Boron (Bn), it was injected intraperitoneally 6 times daily, starting on day 2 after L1210 leukemia cell transplantation. Doses of Bn such as 26; 260 and 2600 μg/kg were used. The determination of intracellular content of cardiolipin, thiols, reactive oxygen species (ROS) and also analysis of Annexin V positivity and mitochondrial transmembrane potential (JC-1 staining) were performed with use of flow cytometry. The levels of “free iron” complexes, transferrin active forms and the rate of NO generation were measured by EPR-specroscopy. Results: Six daily injections of Bn at a dose of 26 μg/kg resulted in an increased survival of mice with L1210 leukemia by 28% (p < 0.05). Bn led to an increase of apoptotic cells number and ROS amount in leukemia cells. Besides, Bn caused a decrease of cardiolipin and nonprotein thiol compounds content. The membrane electrochemical potential of cell mitochondria was decreased also after Bn administration. Studies using EPR-spectroscopy revealed a significant increase in a level of “free iron”, content of transferrin active species and generation rate of NO by inducible NO-synthase in L1210 cells after aminoferrocene administration. Conclusion: Our data indicate that Benzyl-Fc Boron can be promising candidate for realizing a new strategy of anticancer therapy with the use of ROS-inducing agents.

Antileukemic Activity of 4-Demethoxydaunorubicin in Mice

1980 ◽  
Vol 66 (5) ◽  
pp. 549-564 ◽  
Author(s):  
Anna Maria Casazza ◽  
Graziella Pratesi ◽  
Fernando Giuliani ◽  
Aurelio Di Marco
Keyword(s):  
Leukemia Cells ◽  
L1210 Leukemia ◽  
Antileukemic Activity ◽  
Intermittent Schedule ◽  
P388 Leukemia ◽  
Highly Active ◽  
Experimental Mouse

4-demethoxydaunorubicin was tested against experimental mouse leukemias, in comparison with doxorubicin and daunorubicin. 4-demethoxydaunorubicin, administered ip to mice bearing ascitic L1210 or F388 leukemia was 5 times more potent than daunorubicin and 10 times more potent than doxorubicin (potency established in relation to optimal antitumor doses). At the optimal doses, 4-demethoxydaunorubicin was as active as daunorubicin and less active than doxorubicin. 4-demethoxydaunorubicin, administered iv was 8 times more potent than daunorubicin and 4–5 times more potent than doxorubicin. At the optimal doses, 4-demethoxydaunorubicin was markedly more active than daunorubicin or doxorubicin in mice injected iv with 105 L1210 leukemia cells (early or late leukemia) or with 102 Gross leukemia cells. In mice given 2 × 106 Gross leukemia cells iv, 4-demethoxydaunorubicin was as active as doxorubicin when treatment was given iv on day 1, or on days 1 to 3 or 1 to 5. The optimal intermittent schedule was treatment on days 1, 5 and 9 for 4-demethoxydaunorubicin, and on days 1, 3 and 6 for daunorubicin and doxorubicin. 4-demethoxydaunorubicin administered orally was highly active against ascitic P388 leukemia and against L1210 and Gross leukemia inoculated iv.

Sign in / Sign up

Export Citation Format

Share Document